HCW Biologics says TGF-β trap-IL-15 fusion expands CD8+ T, NK cells in human studies
HCWB•Second-generation pipeline and development timeline
The second-generation pipeline now embeds the TGF-β/IL-15 moiety into TRBC-based TCE and ICI constructs.
Lead candidates HCW11-018b and HCW11-040 are IND-enabling, with first clinical studies planned for 2027.
Human and preclinical data on TGF-β trap–IL-15 fusion
HCW Biologics highlighted human data showing its TGF-β trap–IL-15 fusion expanded progenitor CD8+ T cells and NK cells.
The program reported clinical benefit in cancer patients, with the fusion described as well tolerated.
Preclinical work showed activity in models of HIV-1 and bronchopulmonary dysplasia.
